Therorna to Showcase Clinical-Ready Circular RNA in vivo CAR-T and CircRNA Pipeline at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Therorna Inc., a clinical-stage biotechnology company pioneering circular RNA (circRNA)-based therapies, today announced that the company will present three posters at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11–15, 2026, in Boston, Massachusetts. The lead presentation will showcase preclinical data supporting TI-0032, the company’s flagship CD19-targeted, circRNA-based in vivo CAR-T candidate, which recently advanced into a first-in-human investigator-initiated trial (IIT) in patients with recurrent and refractory autoimmune diseases. Two additional posters will feature data from Therorna’s broader pipeline: a circRNA-encoded CD19×CD3 T-cell engager and TI-0093, a circRNA-based HPV16 therapeutic cancer vaccine.
